



## Investor News 2018

The news contents can be obtained from our website [www.investor.bayer.com](http://www.investor.bayer.com)

Date	News
December 20, 2018	Not intended for U.S. and UK Media <b>Bayer receives approval in China for endometriosis treatment Visanne™</b>
December 18, 2018	<b>Bayer extends credit line and increases volume to 4.5 billion euros</b>
December 05, 2018	Capital Markets Day 2018 <b>Bayer to drive value creation as company pursues ambitious growth targets through 2022</b> - Company strongly positioned to benefit from key megatrends - Through 2022, Bayer aims to grow sales by 4 percent, EBITDA before special items by 9 percent and free cash flow by 18 percent annually on average - Adjusted EBITDA margin targets for 2022: Crop Science to exceed 30 percent, Pharmaceuticals to hit more than 35 percent, and Consumer Health to reach approximately 24 percent
November 29, 2018	Group to take comprehensive range of portfolio, efficiency and structural measures <b>Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability</b> - Group plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl's™, and sell its 60-percent interest in Currenta, a site services provider in Germany - Efficiency and structural measures set to enhance competitiveness and generate annual contributions of 2.6 billion euros as of 2022 including the expected synergies from the Monsanto acquisition - A portion of the contributions to be reinvested in core businesses - Total one-time costs expected at a factor of 1.7 times annual contributions - Core earnings per share expected to increase by around 1 euro to 6.80 euros in 2019, with a target of around 10 euros in 2022 - EBITDA margin before special items set to amount to over 30 percent in 2022 - Efficiency and structural measures expected to result in the reduction of around 12,000 of 118,200 jobs worldwide, a significant number of them in Germany
November 27, 2018	Not intended for U.S. and UK Media <b>Bayer receives EU approval for its hemophilia A treatment Jivi®</b> - The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies - Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over time

Date	News
November 27, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion</b></p> <ul style="list-style-type: none"> <li>- First treatment with a tumor-agnostic indication at the time of initial FDA approval</li> <li>- Larotrectinib approved under the brand name Vitrakvi®</li> <li>- 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid tumors in adults and children</li> <li>- Adverse events (AEs) of any grade observed in more than 20 percent of patients, regardless of attribution, included increased ALT (45%), increased AST (45%), anemia (42%), fatigue (37%), nausea (29%), dizziness (28%), cough (26%), vomiting (26%), constipation (23%), and diarrhea (22%)</li> </ul>
November 13, 2018	<p>Third quarter of 2018</p> <p><b>Bayer: Good performance in a challenging environment, Group outlook confirmed</b></p> <ul style="list-style-type: none"> <li>- Group sales increase by 1.9 percent (Fx &amp; portfolio adj.) to 9.905 billion euros</li> <li>- EBITDA before special items level year on year at 2.202 billion euros</li> <li>- Business performance at Pharmaceuticals remains strong</li> <li>- Consumer Health with increase in sales (Fx &amp; portfolio adj.), while currency effects weigh on earnings</li> <li>- Crop Science posts substantial rise in sales and earnings due to acquisition - successful start to integration process</li> <li>- Sales and earnings of Animal Health decline following a strong second quarter</li> <li>- One-time gain (before taxes) of roughly 3.9 billion euros from divestments</li> <li>- Net income 2.886 billion euros</li> <li>- Core earnings per share 1.19 euros</li> <li>- Adjusted 2018 Group outlook confirmed</li> </ul>
October 24, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint</b></p> <p>The safety and tolerability observed in the trial were consistent with previously published data on darolutamide</p>
October 21, 2018	<p>Not intended for U.S. and UK Media - ESMO 2018 Congress (European Society for Medical Oncology)</p> <p><b>Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types</b></p> <ul style="list-style-type: none"> <li>- Data presented across 122 adult and pediatric patients (55 patients from primary dataset plus supplementary dataset with 67 additional patients) with TRK fusion cancer across various tumor types</li> <li>- Integrated dataset on larotrectinib demonstrated high overall response rate of 81 percent (63 percent partial responses and 17 percent complete responses), per investigator assessment</li> <li>- For the initial 55 patients, ongoing responses at 12 months improved to 75 percent with longer follow-up; ongoing responses in the supplementary dataset were 81 percent at 12 months; median duration of response not reached at a respective follow-up of 17.6 and 7.4 months</li> <li>- 84 percent of responding patients in the integrated dataset remained on treatment or underwent surgery for curative intent</li> <li>- Larotrectinib showed favorable safety profile with majority of adverse events grade 1 or 2</li> <li>- Larotrectinib is currently under regulatory review in the EU and U.S.</li> </ul>

Date	News
October 12, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>U.S. FDA approves Bayer's Xarelto® for patients with coronary or peripheral artery disease</b></p> <ul style="list-style-type: none"> <li>- Xarelto, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease</li> <li>- Xarelto, in combination with aspirin, is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient group</li> <li>- Approval in the U.S. follows regulatory clearance in both Europe and Canada</li> </ul>
September 21, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027</b></p> <ul style="list-style-type: none"> <li>- The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies</li> <li>- Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over time</li> </ul>
September 21, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer's Jivi® approved in Japan for hemophilia A</b></p>
September 13, 2018	<p><b>Stefan Oelrich to join Bayer Board of Management and head Pharmaceuticals Division</b></p> <ul style="list-style-type: none"> <li>- Dieter Weinand leaving the company as of November 1, 2018</li> <li>- Contract extensions for Board of Management members Liam Condon and Dr. Hartmut Klusik</li> </ul>
September 05, 2018	<p>Second quarter of 2018</p> <p><b>Bayer completes biggest acquisition in its history</b></p> <ul style="list-style-type: none"> <li>- Monsanto business included on prorated basis from June 7</li> <li>- Group sales advance by 8.5 percent (Fx &amp; portfolio adj.) to 9.481 billion euros</li> <li>- EBITDA before special items increases by 3.9 percent to 2.335 billion euros despite unfavorable currency effects</li> <li>- Pharmaceuticals registers higher sales (Fx &amp; portfolio adj.) but lower earnings - substantial increase in R&amp;D investment</li> <li>- Consumer Health business weak again</li> <li>- Crop Science achieves strong increase in sales and earnings after weak prior-year quarter</li> <li>- Animal Health improves sales (Fx &amp; portfolio adj.) and earnings</li> <li>- Net income amounts to 799 million euros</li> <li>- Core earnings per share up by 1.3 percent at 1.54 euros</li> <li>- Group outlook for 2018 confirmed, with adjustments to reflect</li> </ul>
September 04, 2018	<p><b>LEO Pharma closes acquisition of Bayer's prescription dermatology business in the United States</b></p>
September 03, 2018	<p><b>Brazilian court rules that growers will continue to have access to glyphosate</b></p>
August 30, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer receives US approval for modern hemophilia A treatment Jivi® with a step-wise prophylaxis dosing regimen</b></p> <ul style="list-style-type: none"> <li>- Jivi's extended half-life allows for twice-weekly initial dosing</li> <li>- May be adjusted to every five days and further individually adjusted to less or more frequent dosing</li> </ul>

Date	News
August 27, 2018	<p>New data presented at ESC Congress 2018:</p> <p><b>Results of COMMANDER HF and MARINER studies with rivaroxaban published</b></p> <ul style="list-style-type: none"> <li>- Studies in very sick patient populations reaffirm and further strengthen the safety profile of rivaroxaban</li> <li>- Study results did not show a statistical difference in primary endpoints</li> <li>- COMMANDER HF study evaluated rivaroxaban in patients following an acute decompensation of heart failure and concomitant coronary artery disease</li> <li>- MARINER study evaluated rivaroxaban in acutely medically ill patients</li> </ul>
August 27, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer submits European marketing authorization application for larotrectinib for the treatment of TRK fusion cancer</b></p>
August 24, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer secures approval in the EU for Xarelto® (rivaroxaban) for patients with coronary or peripheral artery disease</b></p> <ul style="list-style-type: none"> <li>- Xarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events</li> <li>- Launch first expected in Germany</li> </ul>
August 20, 2018	<p><b>Decision by Hamburg Regional Court in respect of reporting by WirtschaftsWoche</b></p>
August 17, 2018	<p><b>Bayer rejects WirtschaftsWoche report on Dicamba lawsuits</b></p>
August 16, 2018	<p>Following completion of the divestment of Crop Science businesses to BASF</p> <p><b>Bayer: Conditions for beginning Monsanto integration fulfilled</b></p> <p>Legal remedies against jury verdict in California announced</p>
August 01, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer receives approval of new treatment regimen for Eylea® in the EU</b></p> <ul style="list-style-type: none"> <li>- New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains</li> <li>- Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or more</li> </ul>
July 31, 2018	<p><b>LEO Pharma to expand its lead in medical dermatology with acquisition of Bayer's prescription dermatology unit</b></p> <p>Significant step to bolster LEO Pharma's role as a leading global dermatology company with its goal of helping 125 million patients by 2025</p>
July 27, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery disease</b></p> <ul style="list-style-type: none"> <li>- Positive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS</li> <li>- Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischaemic events</li> </ul>
June 19, 2018	<p><b>Bayer concludes refinancing of the Monsanto acquisition by placing bonds with a volume of 5 billion euros</b></p> <p>Issue of four tranches with maturities of 4 to 11½ years was more than four times oversubscribed</p>

Date	News
June 19, 2018	<p><b>Bayer issues new bonds with a volume of 15 billion U.S. dollars</b></p> <ul style="list-style-type: none"> <li>- Successful international placement secures long-term financing of the Monsanto acquisition</li> <li>- Issue of eight tranches with maturities of three to 30 years was approximately three times oversubscribed</li> </ul>
June 07, 2018	<p><b>Bayer closes Monsanto acquisition</b></p>
June 04, 2018	<p><b>Bayer plans closing of Monsanto acquisition on June 7</b></p> <ul style="list-style-type: none"> <li>- Largest acquisition in company history to double size of agriculture business</li> <li>- Leading innovation engine in agriculture with pro forma R&amp;D investment of 2.4 billion euros in 2017</li> <li>- Transaction anticipated to generate significant value</li> <li>- Bayer strengthens commitment to sustainability and stakeholder engagement</li> <li>- Bayer to remain company name</li> </ul>
June 03, 2018	<p>NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN</p> <p><b>Bayer resolves capital increase with subscription rights to finance the acquisition of Monsanto</b></p> <ul style="list-style-type: none"> <li>- Final equity measure associated with the acquisition</li> <li>- Stockholders can acquire 2 new shares for every 23 shares they hold for 81.00 euros per new share</li> </ul>
May 29, 2018	<p><b>U. S. Department of Justice conditionally approves Bayer's proposed acquisition of Monsanto</b></p> <p>Operations of Bayer and Monsanto to be integrated as soon as divestments to BASF have been accomplished</p>
May 29, 2018	<p>Not intended for U.S. and UK Media</p>
May 25, 2018	<p><b>U.S. FDA accepts larotrectinib New Drug Application and grants priority review</b></p> <p>CEO Werner Baumann at the Annual Stockholders' Meeting of Bayer AG:</p> <p><b>Bayer is making good progress strategically</b></p> <ul style="list-style-type: none"> <li>- Acquisition of Monsanto expected to be closed in the near future</li> <li>- 2017 sales and earnings at the prior-year level</li> <li>- Dividend to be raised for the eighth time in succession - to 2.80 euros per share</li> <li>- Start to fiscal 2018 overshadowed by currency effects</li> </ul>
May 11, 2018	<p><b>Bayer receives approval for Eylea® in China</b></p> <p>Eylea® gains approval in China for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration</p>
May 07, 2018	<p><b>Bayer announces Executive Leadership Team for new Crop Science division</b></p> <p>Liam Condon to lead newly combined organization</p>
May 04, 2018	<p>NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN</p> <p><b>Bayer concludes process to sell Covestro</b></p> <ul style="list-style-type: none"> <li>- 14.2 percent interest sold for 2.2 billion euros</li> <li>- 6.8 percent of shares retained to repay exchangeable bond</li> </ul>
May 03, 2018	<p>NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN</p> <p><b>Bayer initiates full separation from Covestro</b></p> <ul style="list-style-type: none"> <li>- Accelerated bookbuilding process started for 14.2 percent</li> </ul>

Date	News
May 03, 2018	<p>First quarter of 2018</p> <p><b>Bayer: Operational business held back by currency effects - Major progress with Monsanto acquisition</b></p> <ul style="list-style-type: none"> <li>- Group sales increase by 2.0 percent (Fx &amp; portfolio adj.) to 9.138 billion euros</li> <li>- EBITDA before special items down year on year at 2.896 billion euros due to currency effects - level with prior-year quarter on a currency-adjusted basis</li> <li>- Sales increase at Pharmaceuticals (Fx &amp; portfolio adj.)</li> <li>- Consumer Health down year on year, as expected</li> <li>- Sales of Crop Science match strong prior-year quarter (Fx &amp; portfolio adj.)</li> <li>- Animal Health raises sales (Fx &amp; portfolio adj.) and earnings</li> <li>- Net income declines by 6.2 percent to 1.954 billion euros</li> <li>- Core earnings per share down 1.3 percent at 2.28 euros</li> <li>- European Commission and additional regulators conditionally approve Monsanto acquisition</li> <li>- Currency adjusted Group outlook for 2018 confirmed</li> </ul>
April 26, 2018	<p>Issues raised by regulatory authorities in respect of Monsanto acquisition addressed:</p> <p><b>Bayer signs agreement to sell further Crop Science businesses to BASF for up to 1.7 billion euros</b></p> <ul style="list-style-type: none"> <li>- Package includes global vegetable seeds business, certain seed treatments and digital farming activities</li> <li>- Businesses generated total sales of 745 million euros in 2017</li> <li>- Sale is subject to successful closing of Monsanto acquisition</li> </ul>
April 16, 2018	<p><b>Temasek subscribes to capital increase and acquires approximately 3.6 percent of Bayer</b></p> <p>Investment by renowned long-term investor affirms Bayer's strategy</p>
March 26, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer announces completion of rolling submission of New Drug Application in the U.S. for larotrectinib for the treatment of TRK fusion cancer</b></p>
March 21, 2018	<p><b>European Commission conditionally approves Bayer's proposed acquisition of Monsanto</b></p> <p>Closing of transaction planned for the second quarter of 2018</p>
March 07, 2018	<p><b>Bayer in exclusive talks with BASF on the sale of vegetable seeds business</b></p>
February 28, 2018	<p>Fiscal 2017:</p> <p><b>Bayer: business at prior-year level - on track with strategy</b></p> <ul style="list-style-type: none"> <li>- Group sales increased by 1.5 percent (Fx &amp; portfolio adj.) to 35.015 billion euros</li> <li>- Another record year for Pharmaceuticals</li> <li>- Weak business development at Consumer Health</li> <li>- Crop Science business down against prior year due to situation in Brazil – measures taking effect</li> <li>- EBITDA before special items level year on year at 9.288 billion euros</li> <li>- Net income raised by 61.9 percent to 7.336 billion euros</li> <li>- Core earnings per share increased by 1.0 percent to 6.74 euros</li> <li>- Covestro deconsolidated - additional cash inflows of 4.7 billion euros</li> <li>- Monsanto acquisition expected to close in second quarter of 2018</li> <li>- Group outlook for 2018: increase in sales (Fx &amp; portfolio adj.), EBITDA before special items and core earnings per share at prior-year level due to currency effects</li> </ul>
February 27, 2018	<p><b>Bayer proposes increased dividend for 2017 of 2.80 euros per share</b></p> <p>Payment per share rises 3.7 percent</p>
February 13, 2018	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer receives first approval for Eylea® in China</b></p> <p>Eylea is the first anti-VEGF drug approved in China for the treatment of visual impairment due to diabetic macular edema in patients with DME</p>

Date	News
February 12, 2018	Not intended for U.S. and UK Media <b>New data for aflibercept show prolonged injection intervals</b> - Data from ALTAIR study demonstrate injection appointments at an interval of 12 weeks or more - New data submitted to EMA to update the current product information
January 16, 2018	Not intended for U.S. or UK Media <b>FDA report reaffirms safety profile and effectiveness of Bayer's Xarelto® in routine clinical practice</b>
January 11, 2018	NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN <b>Bayer sells 10.4 percent stake in Covestro</b> Placement volume considerably higher than planned
January 10, 2018	NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN <b>Bayer further reduces holding in Covestro</b> Accelerated bookbuilding process started